ALK and neuroblastoma: A preclinical study by Wood et al. showed that dual inhibition with a CDK4/6 inhibitor like ribociclib and ALK inhibitor such as ceritinib can lead to complete regression of ALK-aberrant neuroblastoma xenograft tumors164.